SCHEMBL2471390

SCHEMBL2471390

O=c1c(OCc2ccccc2)cc(-c2ccc(Cl)c(C(F)(F)F)c2)cn1C(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
MAOB P27338 1/20 0.38
S1PR1 P21453 2/20 0.37
MRGPRX4 Q96LA9 3/20 0.37
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
COMT P21964 1/20 0.37
PTGER1 P34995 1/20 0.37
MCL1 Q07820 1/20 0.37
MAPK14 Q16539 4/20 0.37
PTPN2 P17706 1/20 0.36
PTPN1 P18031 1/20 0.36
PTPN6 P29350 1/20 0.36
SLC6A4 P31645 1/20 0.36
RXRA P19793 2/20 0.36
RXRB P28702 2/20 0.36
RXRG P48443 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2465241 0.91 MAOB (0.39) PPARGPPARAMAOBS1PR1MRGPRX4
SCHEMBL2469202 0.76 COMT (0.49) COMT
SCHEMBL2468053 0.73 MAPK14 (0.45) MAOBPTGER1MAPK14SLC6A4
SCHEMBL2538807 0.68 PPARG (0.41) PPARGPPARAS1PR1PTGER1
SCHEMBL6532746 0.67 MAPK14 (0.49) MAOBMAPK14
SCHEMBL22787011 0.67 KDM4E (0.42) PPARGPPARAS1PR1MRGPRX4
SCHEMBL1041571 0.66 NOTUM (0.53)
SCHEMBL2466707 0.66 COMT (0.51) COMT
SCHEMBL20756090 0.64 RXRA (0.54) MRGPRX4MAPK14SLC6A4RXRARXRB
SCHEMBL2698021 0.64 NOTUM (0.61) COMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9309199-B2 Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders MERCK SHARP & DOHME CORP. (US) 2016-04-12 US disclosed
EP-2542077-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS Merck Sharp & Dohme Corp. (US) 2013-01-09 EP disclosed
US-20130005744-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME LLC 2013-01-03 US disclosed
WO-2011109261-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME CORP. (US) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005744-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS COMT, PNMT, TPMT PPARG 2229/4885PPARA 2620/4885MAOB 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.